title: Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
authors.affiliation: Department of Experimental Therapeutics, Houston, TX, USA.
authors.forename: F
authors.initials: F
authors.lastname: Cervantes-Gomez
authors.affiliation: Department of Experimental Therapeutics, Houston, TX, USA.
authors.forename: V
authors.initials: V
authors.lastname: Kumar Patel
authors.affiliation: Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
authors.forename: P
authors.initials: P
authors.lastname: Bose
authors.affiliation: Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Keating
authors.affiliation: Department of Experimental Therapeutics, Houston, TX, USA.|Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
authors.forename: V
authors.initials: V
authors.lastname: Gandhi
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000201:enzymology*; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis* / Q000187:drug effects; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine